Background/Purpose Psoriasis and psoriatic arthritis (PsA) are closely linked inflammatory conditions that can affect both children and adults. In children, these diseases are associated with traditional cardiovascular disease risk factors and subclinical atherosclerosis. In older adults, systemic inflammation from psoriasis and PsA accelerates atherosclerosis, and these conditions are independent risk factors for severe cardiovascular disease…
In this episode, Dr. Bharat Kumar offers some advice to aspiring rheumatologists on how to present themselves in the best light possible in their application essays. He also offers a sneak peek at the rest of the compelling content in the November issue of The Rheumatologist.
Fava et al. investigated longitudinal autoantibody profiles in patients with lupus nephritis (LN) to define serological biomarkers of histologic class. They found that baseline levels of anti-C1q and anti-double-stranded DNA antibodies may serve as noninvasive biomarkers of proliferative LN and anti-C1q antibodies may predict complete response.
An understanding of the mechanisms underlying NET-mediated inflammation will empower clinicians to target therapies that can mitigate disease activity & improve outcomes in patients with lupus.
The Alliance for Transparent and Affordable Prescriptions’ board members for the 2024–25 cycle include Marcus Snow, MD, and Howard Blumstein, MD, who both have a strong history of volunteer leadership in the ACR.
The Underwater Biosimilars Coalition shared with the Centers for Medicare & Medicaid Services concerns about problems arising from the average sales price payment methodology and discussed potential options for addressing these challenges.
At the November meeting, the ACR will advance a resolution that addresses increasing access to telemedicine services for Medicare beneficiaries.
A letter from 233 bipartisan members of Congress last week urged House leadership to replace the 2.8% cut proposed in the FY2025 Physician Fee Schedule with an annual payment update reflective of inflationary pressures before the end of the year. Boost this effort by contacting your legislator today.
There’s still time to contribute and attend RheumPAC’s event at ACR Convergence 2024. If you haven’t yet made your 2024 donation, this is the best time to do so—thanks to generous champions, every contribution will be amplified.
A phase 2 clinical trial has demonstrated the effectiveness for multiple doses of subcutaneous sonelokimab for the treatment of adults with active psoriatic arthritis.